All In Biotech

Drug Trial Radar · NCT06738745

Study of HRS-2189 Combined HRS-5041 in Prostate Cancer

A Phase II Study of HRS-2189 Combined HRS-5041 in Metastatic Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Dec 31, 2024

Primary completion

Jan 31, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Our study is aimed to evaluate the efficacy and safety of HRS-2189 combined with HRS-5041 in metastatic prostate cancer.

Conditions

  • Prostate Cancer Metastatic Disease

Interventions

  • HRS-2189Drug

    HRS-2189

  • HRS-5041Drug

    HRS-5041

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PSA50Time frame: up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan Cancer Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.